Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H4TQ
|
|||
| Former ID |
DAP001248
|
|||
| Drug Name |
Thyrotropin Alfa
|
|||
| Indication | Thyroid cancer [ICD-11: 2D10; ICD-10: C73; ICD-9: 193] | Approved | [1] | |
| Therapeutic Class |
Diagnostic Agents
|
|||
| SuperDrug ATC ID |
H01AB01; V04CJ01
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thyrotropin receptor (TSHR) | Target Info | Binder | [2], [3] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Thyroid hormone synthesis | ||||
| Autoimmune thyroid disease | ||||
| NetPath Pathway | Wnt Signaling Pathway | |||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Reactome | Hormone ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Peptide GPCRs | |||
| TSH signaling pathway | ||||
| Thyroxine (Thyroid Hormone) Production | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020898. | |||
| REF 2 | Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg). Nippon Yakurigaku Zasshi. 2009 Jul;134(1):28-34. | |||
| REF 3 | Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation. N Engl J Med. 2008 Sep 18;359(12):1295-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.